Survey of NANN Members Indicated Preference for New Heelstick ‘Pull Trigger’ Activation Design
ATLANTA, Aug. 14—MediPurpose®, a master distributor and manufacturer of medical devices, today announced the publication of a white paper related to the redesign of its recently launched babyLance® infant heel incision device.
Inventing a Better babyLance® Heel Incision Device: Listening to End Users—Heelstick Trigger Activation Survey at the 2011 NANN Conference illustrates key findings from a survey that MediPurpose conducted at the National Association of Neonatal Nurses’ 2011 Annual Educational Conference.
The survey gauged NANN members’ preferences between MediPurpose’s original babyLance infant incision device’s “push-forward trigger” activation mechanism and a newly designed prototype’s “pull trigger.”
The white paper’s key findings indicate a majority preference for a new design’s pull trigger, validating the company’s decision to move forward with a redesign of its heelstick device.
Listening to the End User
“Throughout the reinvention process, MediPurpose listened carefully to babyLance’s end users, resulting in a new neonatal heelstick device that will satisfy the unique needs of both its end-user customers and distribution partners,” said MediPurpose founder and CEO Patrick Yi.
Yi said that his company’s confidence is fostered by the knowledge that its new infant heelstick device:
Is designed with intensive input from a diverse range of highly qualified users.
Provides a preferred pull trigger activation mechanism that is comfortable and easy to use.
Is assured to provide safety and quality from a proven and trusted manufacturer with worldwide distribution channels.
Additionally, Yi said that the interactive process further validates MediPurpose’s medical product innovation process and capabilities.
About babyLance® Infant Heel Incision Devices
The new babyLance infant heel incision device is a fully redesigned iteration of MediPurpose’s original safe, easy and effective heelstick device.
Used by neonatal caregivers to collect blood samples from infants, the new babyLance features an ergonomic design to provide a secure and stable grip.
Combined with a redesigned trigger mechanism, the heelstick device is easy to activate, helping to deliver a consistent incision without touching the baby’s tender nerve fibers.
babyLance heelstick devices are available in two models:
The babyLance BLN (Newborn), which delivers an incision depth of 1.00 mm.
The babyLance BLP (Preemie), which delivers an incision depth of 0.85 mm.
To download the white paper, please visit www.medipurpose.com/downloads.
For more information about babyLance—including pricing and no-cost product sample requests—please visit www.medipurpose.com/babylance.
Founded in 1999, MediPurpose is an innovative medical device company headquartered in Singapore, with offices in the United States and Europe.
Known for its popular babyLance™ safety heelstick, SurgiLance™ safety lancet and MediPlus™ advanced wound care products, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor that provides unique solutions for both medical product manufacturers and distributors.
MediPurpose's Innovation division offers angel funding and developmental expertise for new medical device inventors and innovative medical product companies that seek entrance into new medical device markets.
For more information about MediPurpose’s medical products and solutions for inventors, innovators, manufacturers and distributors, please visit www.medipurpose.com.